Malkan, Ü. Y. Et Al. 2018. Lenalidomide provide better progression free survival than thalidomide and bortezomib in the first relapse of multiple myeloma patients after autologous transplantation. 9th International Eurasian Hematology Oncology Congress (EHOC) , (İstanbul, Turkey).

Malkan, Ü. Y., Buyukasik, Y., Demiroglu, H., Ciftciler, R., Gunes, G., Okay, M., ... Aladag, E.(2018). Lenalidomide provide better progression free survival than thalidomide and bortezomib in the first relapse of multiple myeloma patients after autologous transplantation . 9th International Eurasian Hematology Oncology Congress (EHOC), İstanbul, Turkey

Malkan, ÜMİT Et Al. "Lenalidomide provide better progression free survival than thalidomide and bortezomib in the first relapse of multiple myeloma patients after autologous transplantation," 9th International Eurasian Hematology Oncology Congress (EHOC), İstanbul, Turkey, 2018

Malkan, ÜMİT Y. Et Al. "Lenalidomide provide better progression free survival than thalidomide and bortezomib in the first relapse of multiple myeloma patients after autologous transplantation." 9th International Eurasian Hematology Oncology Congress (EHOC) , İstanbul, Turkey, 2018

Malkan, Ü. Y. Et Al. (2018) . "Lenalidomide provide better progression free survival than thalidomide and bortezomib in the first relapse of multiple myeloma patients after autologous transplantation." 9th International Eurasian Hematology Oncology Congress (EHOC) , İstanbul, Turkey.

@conferencepaper{conferencepaper, author={ÜMİT YAVUZ MALKAN Et Al. }, title={Lenalidomide provide better progression free survival than thalidomide and bortezomib in the first relapse of multiple myeloma patients after autologous transplantation}, congress name={9th International Eurasian Hematology Oncology Congress (EHOC)}, city={İstanbul}, country={Turkey}, year={2018}}